Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Leading USA based genetic testing brand officially enters the Indian market
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
New facility is part of Aptar Pharma’s global expansion program
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Subscribe To Our Newsletter & Stay Updated
